If passed, TROA would: Permanently allow Medicare Part D to cover FDA-approved anti-obesity medications Expand Medicare Part B coverage of intensive behavioral therapy for obesity to include a wider range of providers (not just primary care physicians) However, in April 2025, CMS announced it would not include Medicare Part D coverage of obesity drugs in its rule changes for 2026, stating the proposal was "not appropriate at this time." That decision pushed the issue back to Congress, where the TROA remains under consideration
As of early 2026, the most effective GLP-1 drug for weight loss is tirzepatide (Mounjaro, Zepbound)
Clinical Update 5/30/2017 Olive Oil Helps in Pre-Diabetes Adding extra virgin olive oil to a meal decreased the rise in blood sugar and increased insulin levels after the meal, according to a new study in people with pre-diabetes
Desai A, Khataniar H, Tabaku F, Hashash JG, Farraye FA, Kochhar GS